FY2017 EPS Estimates for Ekso Bionics Holdings, Inc. Cut by Analyst (EKSO)
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Equities research analysts at SunTrust Banks cut their FY2017 EPS estimates for shares of Ekso Bionics Holdings in a note issued to investors on Wednesday. SunTrust Banks analyst B. Nudell now forecasts that the company will earn ($0.81) per share for the year, down from their previous estimate of ($0.64). SunTrust Banks also issued estimates for Ekso Bionics Holdings’ Q4 2017 earnings at ($0.10) EPS, FY2018 earnings at ($0.35) EPS, FY2019 earnings at ($0.27) EPS and FY2021 earnings at ($0.16) EPS.
Ekso Bionics Holdings (NASDAQ:EKSO) last released its earnings results on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%. The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million.
Separately, Zacks Investment Research cut shares of Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th.
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) opened at $1.53 on Monday. Ekso Bionics Holdings has a one year low of $0.99 and a one year high of $4.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73.
In other Ekso Bionics Holdings news, insider Russ Angold sold 28,254 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $1.53, for a total transaction of $43,228.62. Following the sale, the insider now owns 250,678 shares in the company, valued at approximately $383,537.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have acquired 41,264 shares of company stock worth $48,255 and have sold 259,352 shares worth $399,373. 7.10% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in EKSO. Carl Domino Inc raised its position in shares of Ekso Bionics Holdings by 74.7% during the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after buying an additional 35,088 shares during the last quarter. Intellectus Partners LLC raised its position in shares of Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares during the last quarter. National Planning Corp raised its position in shares of Ekso Bionics Holdings by 116.2% during the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the last quarter. Hedge funds and other institutional investors own 2.85% of the company’s stock.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.